Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 5/20 | 0.58 |
| ▸ | FLT3 | P36888 | 4/20 | 0.57 |
| ▸ | MELK | Q14680 | 6/20 | 0.52 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | FER | P16591 | 1/20 | 0.52 |
| ▸ | MATK | P42679 | 1/20 | 0.52 |
| ▸ | BLK | P51451 | 1/20 | 0.52 |
| ▸ | BMX | P51813 | 1/20 | 0.52 |
| ▸ | TEK | Q02763 | 1/20 | 0.52 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.52 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.52 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.52 |
| ▸ | CSK | P41240 | 1/20 | 0.50 |
| ▸ | CAMK1G | Q96NX5 | 1/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829605 | 0.95 | FLT3 (0.59) | CCR4FLT3MELKBTKERBB4 | |
| SCHEMBL17829812 | 0.81 | CCR4 (0.56) | CCR4FLT3MELKBTKERBB4 | |
| SCHEMBL17833002 | 0.78 | CCR4 (0.47) | CCR4 | |
| SCHEMBL17829804 | 0.78 | CCR4 (0.64) | CCR4FLT3MELKBTKERBB4 | |
| SCHEMBL17831897 | 0.77 | CCR4 (0.44) | CCR4CACNA2D1 | |
| SCHEMBL17829618 | 0.77 | CCR4 (0.53) | CCR4FLT3MELKCACNA2D1 | |
| SCHEMBL17832984 | 0.76 | FLT3 (0.55) | FLT3 | |
| SCHEMBL17829974 | 0.75 | CCR4 (0.58) | CCR4FLT3MELKCACNA2D1 | |
| SCHEMBL17833178 | 0.75 | CCR4 (0.55) | CCR4FLT3BTKERBB4CSK | |
| SCHEMBL17829825 | 0.74 | CCR4 (0.54) | CCR4FLT3MELKBTKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | CCR4 4472/4885FLT3 870/4885MELK 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.